IRON OXIDE MAGNETIC NANOPARTICLES MODIFIED WITH BIOMOLECULES FOR THERANOSTIC APPLICATIONS

Danai Prokopiou^{1,2}, Vladan Kusigerski³, Sanja Vranjes-Duric³, Eleni K. Efthimiadou^{1,2}

¹ Institute of Nanoscience and Nanotechnology, National Center for Scientific Research "Demokritos", Athens, Greece

² Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece

³ Laboratory for Radioisotopes, Vinča Institute of Nuclear Sciences, University of Belgrade, P. O. Box 522, 11001 Belgrade, Serbia

Iron Oxide Magnetic Nanoparticles (IONPs) attract great interest on the scientific community due to their broad spectrum of applications. As theranostic agents can be used aiming to improve cancer diagnosis and treatment in early stage, reducing simultaneously the side effects on normal tissues (magnetic drug targeting) [1]. One of the most known therapeutic approach is hyperthermia on the site of tumor by using alternate magnetic field. Furthermore, the IONPs used as contrasts agents (*in vivo*) in MRI, in gene transformation, biosensors, enzyme immobilization, immunoassays, purification (*in vitro*) and so on [2].

In the present work we synthesized, full characterized and evaluated the modified carboxylate mNPs that coated first with the co-polymer PEG-*co*-PLA (mNPs@PEG-*co*-PLA) through carbodiimide chemistry. The coated mNPs are studied about their loading and release ability of the anticancer drug doxorubicin (DOX). Following the mNPs conjugated with the cyclic Arg-Gly-Asp peptide cRGDfK-Orn3-CGG (mNPs@cRGD) as a targeting peptide through maleimide. Morphological and structural characterization as well as hyperthermia measurements were performed in order to evaluate their heating ability. Both targeted and non- targeted mNPs were radiolabeled with ¹¹⁷Lu performing *in-vitro* stability as well as *in-vivo* biodistribution in healthy mice. To investigate the cellular uptake of IONPs we used Prussian Blue assay to identify the mNPs localization and endocytosis mechanism.

References:

[1"*Magnetic nanoparticles: synthesis, protection, functionalization, and application.*",Lu, A.H., E.L. Salabas, and F. Schuth, Angew Chem Int Ed Engl, **46**(8): p. 1222-44, 2007.

[2] "*Interaction of metal oxide nanoparticles with lung surfactant protein A*." Schulze, C., U.F. Schaefer, C.A. Ruge, W. Wohlleben, and C.M. Lehr, Eur J Pharm Biopharm, **77**(3): p. 376-83, 2011.